[go: up one dir, main page]

CL2019003228A1 - Composiciones farmacéuticas de atropina. - Google Patents

Composiciones farmacéuticas de atropina.

Info

Publication number
CL2019003228A1
CL2019003228A1 CL2019003228A CL2019003228A CL2019003228A1 CL 2019003228 A1 CL2019003228 A1 CL 2019003228A1 CL 2019003228 A CL2019003228 A CL 2019003228A CL 2019003228 A CL2019003228 A CL 2019003228A CL 2019003228 A1 CL2019003228 A1 CL 2019003228A1
Authority
CL
Chile
Prior art keywords
atropine
pharmaceutical compositions
compositions
formulations
free
Prior art date
Application number
CL2019003228A
Other languages
English (en)
Inventor
Navneet Puri
Prem Sagar Akasapu
Irfan A Mohammed
Kumaresh Soppimath
Iouri V Ilitchev
Tao Zhang
Original Assignee
Nevakar Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64096170&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2019003228(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nevakar Inc filed Critical Nevakar Inc
Publication of CL2019003228A1 publication Critical patent/CL2019003228A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/08—Mydriatics or cycloplegics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

EL TEMA DE LA INVENCIÓN SE DIRIGE A COMPOSICIONES Y MÉTODOS PARA FORMULACIONES DE ATROPINA EN DOSIS BAJA, ESTÉRILES Y ESTABLES EN ALMACENAMIENTO, CON ESTABILIDAD MEJORADA. PREFERENTEMENTE, LAS COMPOSICIONES PRESENTADAS EN EL PRESENTE DOCUMENTO ESTÁN SUSTANCIALMENTE LIBRES DE PRESERVANTES Y EXHIBEN MENOS DEL 0,35% DE ÁCIDO TRÓPICO POR DEGRADACIÓN DE ATROPINA. VENTAJOSAMENTE, LAS FORMULACIONES CONTEMPLADAS TAMBIÉN ESTÁN SUSTANCIALMENTE LIBRES DE PRESERVANTES.
CL2019003228A 2017-05-11 2019-11-11 Composiciones farmacéuticas de atropina. CL2019003228A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762505027P 2017-05-11 2017-05-11

Publications (1)

Publication Number Publication Date
CL2019003228A1 true CL2019003228A1 (es) 2020-01-31

Family

ID=64096170

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019003228A CL2019003228A1 (es) 2017-05-11 2019-11-11 Composiciones farmacéuticas de atropina.

Country Status (23)

Country Link
US (14) US10251875B2 (es)
EP (2) EP3548000B1 (es)
JP (5) JP6557379B2 (es)
KR (1) KR102281667B1 (es)
CN (1) CN110621298B (es)
AU (1) AU2018265257B2 (es)
CA (1) CA3063228C (es)
CL (1) CL2019003228A1 (es)
CO (1) CO2019012893A2 (es)
CY (1) CY1124880T1 (es)
ES (1) ES2901140T3 (es)
HR (1) HRP20212019T1 (es)
HU (1) HUE056595T2 (es)
LT (1) LT3548000T (es)
MX (1) MX392558B (es)
PH (1) PH12019502701A1 (es)
PL (1) PL3548000T3 (es)
PT (1) PT3548000T (es)
RS (1) RS62817B1 (es)
RU (1) RU2745603C1 (es)
SG (1) SG11201910085UA (es)
SI (1) SI3548000T1 (es)
WO (1) WO2018209051A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10154923B2 (en) 2010-07-15 2018-12-18 Eyenovia, Inc. Drop generating device
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
HK1248570A1 (zh) 2015-05-29 2018-10-19 西德奈克西斯公司 D2o稳定化的药物制剂
AR108591A1 (es) * 2016-05-25 2018-09-05 Singapore Health Serv Pte Ltd Composición acuosa que contiene atropina
EP3548000B1 (en) * 2017-05-11 2021-11-10 Vyluma Inc. Atropine pharmaceutical compositions
AU2018279940B2 (en) 2017-06-10 2023-12-14 Eyenovia, Inc. Methods and devices for handling a fluid and delivering the fluid to the eye
US11554115B2 (en) * 2018-03-14 2023-01-17 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Quinoline derivative for treatment of triple-negative breast cancer
WO2019216395A1 (ja) * 2018-05-11 2019-11-14 千寿製薬株式会社 眼科用組成物
CN110934816B (zh) * 2018-09-25 2022-04-08 沈阳兴齐眼科医院有限公司 一种提高低浓度阿托品眼用制剂稳定性的方法
WO2020219707A1 (en) * 2019-04-24 2020-10-29 Allergan, Inc. Compositions and methods for treatment of ocular conditions
WO2021001806A1 (en) * 2019-07-04 2021-01-07 Ocular Discovery Ltd. Stable dipyridamole formulations with reduced impurities
CA3164288A1 (en) 2019-12-11 2021-06-17 Eyenovia, Inc. Systems and devices for delivering fluids to the eye and methods of use
IL293859A (en) * 2019-12-16 2022-08-01 Sydnexis Inc Ophthalmic compositions comprising d2o
CN110917133A (zh) * 2019-12-23 2020-03-27 河北科技大学 一种治疗近视的滴眼剂及其制备方法
EP4146148A1 (en) * 2020-05-05 2023-03-15 The Procter & Gamble Company Oral care compositions comprising dicarboxylic acid
CN111821259A (zh) * 2020-07-14 2020-10-27 艾尔健康眼药(辽宁)有限公司 一种眼用药物组合物
CN111840221A (zh) * 2020-08-25 2020-10-30 安徽博诺美科生物医药有限公司 一种硫酸阿托品滴眼液
WO2022130033A1 (en) * 2020-12-17 2022-06-23 Sun Pharmaceutical Industries Limited An aqueous sterile solution of atropine for ophthalmic use
CA3211874A1 (en) * 2021-03-16 2022-09-22 Kumaresh Soppimath Multi-dose container for ophthalmic compositions
EP4088713A1 (en) 2021-05-10 2022-11-16 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Ophthalmic pharmaceutical composition comprising atropine
EP4088714A1 (en) 2021-05-10 2022-11-16 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Ophthalmic pharmaceutical composition comprising atropine
CN113440486B (zh) * 2021-06-02 2022-12-20 苏州欧康维视生物科技有限公司 一种用于预防或治疗眼科疾病的滴眼剂组合物及其制备方法
CN117295491A (zh) * 2021-09-13 2023-12-26 安徽欧普视方医药科技有限公司 阿托品滴眼液及其制备方法
WO2023086878A1 (en) * 2021-11-10 2023-05-19 Visus Therapeutics, Inc. Carbachol formulations to enhance anti-presbyopia effects
CN114129511A (zh) * 2021-12-07 2022-03-04 河南润弘制药股份有限公司 一种具有改进稳定性的硫酸阿托品注射液
WO2023152642A1 (en) * 2022-02-08 2023-08-17 Avaca Pharma Private Limited Ophthalmic compositions and methods thereof
US20230277521A1 (en) * 2022-03-07 2023-09-07 Harrow Ip, Llc Extended-release pharmaceutical compositions for treating eye conditions
CN114569551A (zh) * 2022-03-21 2022-06-03 杭州赫尔斯科技有限公司 阿托品滴眼液及其制备方法
WO2023201315A2 (en) * 2022-04-14 2023-10-19 TearClear Corp. Ophthalmic agent in preservative removal device
CN115177584A (zh) * 2022-07-14 2022-10-14 成都市海通药业有限公司 一种硫酸阿托品注射液的制备方法
WO2024091789A1 (en) * 2022-10-26 2024-05-02 Vyluma Inc. Childhood atropine for myopia progression
CN115998692A (zh) * 2023-02-15 2023-04-25 苏州欧康维视生物科技有限公司 一种阿托品药物产品及其用途
WO2025146828A1 (ja) * 2024-01-05 2025-07-10 ロート製薬株式会社 眼科組成物

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU86521A1 (fr) 1986-07-18 1988-02-02 Oreal Procede de teinture des cheveux avec des colorants hydroxyquinoniques et des sels metalliques
IL85312A (en) 1988-02-03 1991-08-16 Israel State Injectable pharmaceutical compositions having improved stability
JP2617508B2 (ja) * 1988-02-05 1997-06-04 エーザイ株式会社 安定なジフェンヒドラミン含有水溶液
US5460834A (en) * 1991-12-13 1995-10-24 Alcon Laboratories, Inc. Combinations of polymers for use in physiological tear compositions
US5716952A (en) * 1992-03-18 1998-02-10 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of muscarinic antagonists
SE9401108D0 (sv) * 1994-03-31 1994-03-31 Leiras Oy Ophthalmic composition I
US20030129083A1 (en) 1997-11-26 2003-07-10 Advanced Medical Optics, Inc. Multi purpose contact lens care compositions including propylene glycol or glycerin
US6164282A (en) 1999-01-27 2000-12-26 Allergan Sales, Inc. Methods for restoring and/or enhancing accommodation in pseudo phakia
JP2004503593A (ja) * 2000-07-14 2004-02-05 アラーガン、インコーポレイテッド 増大した溶解度を持つ治療活性成分を含む組成物
US20020198209A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US7851504B2 (en) 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
CN101049287A (zh) 2006-04-07 2007-10-10 财团法人长庚纪念医院 抑制近视度数增加的低浓度阿托平眼药剂及其制造方法
US20070254914A1 (en) * 2006-05-01 2007-11-01 Non-Profit Organization Chang Gung Memorial Hospital Low-concentration atropine solution for preventing myopia progression and preparing method thereof
JP2007308398A (ja) * 2006-05-17 2007-11-29 Chang Gung Memorial Hospital 目薬、及びその製造方法
MX2010003774A (es) * 2007-10-08 2010-04-27 Fovea Pharmaceuticals Sa Formulaciones oftalmicas acuosas.
US8883214B2 (en) 2009-01-13 2014-11-11 The Regents Of The University Of California Implantable delivery vehicle for ocular delivery of muscarinic antagonists
US20120203161A1 (en) 2009-08-12 2012-08-09 Seros Medical, Llc Deuterated water and riboflavin solution for extending singlet oxygen lifetimes in treatment of ocular tissue and method of use
WO2012161655A1 (en) 2011-05-23 2012-11-29 Singapore Health Services Pte Ltd Composition and/or method for reducing and/or preventing myopia progression comprising atropine
BR112015017708A2 (pt) * 2013-01-31 2017-07-11 Senju Pharma Co solução aquosa estável
KR102027663B1 (ko) 2013-05-06 2019-10-01 가오슝 창 궁 메모리얼 하스피털 약학적 조성물 및 이의 용도
WO2015055301A1 (en) * 2013-10-15 2015-04-23 Pharmathen S.A. Preservative free pharmaceutical compositions for ophthalmic administration
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US9421199B2 (en) * 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
US20160009705A1 (en) * 2014-06-24 2016-01-14 Sydnexis, Inc. Ophthalmic composition
WO2016013993A1 (en) 2014-07-25 2016-01-28 Imuneks Farma Llac Sanayi Ve Ticaret A.Ş. Stable preservative free ophthalmic formulations of opioid antagonists
WO2016187426A1 (en) 2015-05-19 2016-11-24 Amorphex Therapeutics Llc A device that delivers a sustained low-dose of a myopia-suppressing drug
CA2987787C (en) 2015-06-18 2023-06-27 Presbyopia Therapies, LLC Compositions for the improvement of distance vision and the treatment of refractive errors of the eye
AR108591A1 (es) 2016-05-25 2018-09-05 Singapore Health Serv Pte Ltd Composición acuosa que contiene atropina
EP3548000B1 (en) * 2017-05-11 2021-11-10 Vyluma Inc. Atropine pharmaceutical compositions
US11191751B1 (en) 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions

Also Published As

Publication number Publication date
JP6557379B2 (ja) 2019-08-07
AU2018265257A1 (en) 2019-11-14
US11707458B2 (en) 2023-07-25
JP6865476B2 (ja) 2021-04-28
AU2018265257B2 (en) 2020-08-06
BR112019023515A2 (pt) 2020-05-19
CA3063228C (en) 2022-06-28
US20190175579A1 (en) 2019-06-13
US20230355604A1 (en) 2023-11-09
USRE50040E1 (en) 2024-07-16
US20190192499A1 (en) 2019-06-27
ES2901140T3 (es) 2022-03-21
KR102281667B9 (ko) 2024-01-08
US20240342154A1 (en) 2024-10-17
US11730728B2 (en) 2023-08-22
WO2018209051A1 (en) 2018-11-15
EP3970694A1 (en) 2022-03-23
HRP20212019T1 (hr) 2022-04-01
JP2019172704A (ja) 2019-10-10
CO2019012893A2 (es) 2020-02-28
MX392558B (es) 2025-03-24
US11642338B2 (en) 2023-05-09
US10251875B2 (en) 2019-04-09
US20190209545A1 (en) 2019-07-11
US20190183876A1 (en) 2019-06-20
US20190175580A1 (en) 2019-06-13
PL3548000T3 (pl) 2022-01-17
JP6681503B2 (ja) 2020-04-15
US10576074B2 (en) 2020-03-03
US12036217B2 (en) 2024-07-16
US11730727B2 (en) 2023-08-22
CN110621298B (zh) 2022-12-20
JP2019194248A (ja) 2019-11-07
JP2019172705A (ja) 2019-10-10
CY1124880T1 (el) 2022-11-25
EP3548000A4 (en) 2019-12-04
SI3548000T1 (sl) 2022-02-28
US10610525B2 (en) 2020-04-07
US11071732B2 (en) 2021-07-27
RS62817B1 (sr) 2022-02-28
LT3548000T (lt) 2022-03-10
KR20190138714A (ko) 2019-12-13
CA3063228A1 (en) 2018-11-15
JP6681502B2 (ja) 2020-04-15
MX2019013218A (es) 2022-05-24
US20180325888A1 (en) 2018-11-15
CN110621298A (zh) 2019-12-27
US11464769B2 (en) 2022-10-11
PT3548000T (pt) 2021-12-10
US20200397775A1 (en) 2020-12-24
KR102281667B1 (ko) 2021-07-23
JP2018188440A (ja) 2018-11-29
US10583132B2 (en) 2020-03-10
JP7332179B2 (ja) 2023-08-23
EP3548000A1 (en) 2019-10-09
PH12019502701A1 (en) 2020-12-07
EP3548000B1 (en) 2021-11-10
JP2021102647A (ja) 2021-07-15
RU2745603C1 (ru) 2021-03-29
US20210128546A1 (en) 2021-05-06
US10568875B2 (en) 2020-02-25
HUE056595T2 (hu) 2022-02-28
NZ758555A (en) 2021-10-29
SG11201910085UA (en) 2019-11-28
US20200405705A1 (en) 2020-12-31
US20200397776A1 (en) 2020-12-24
US20200352928A1 (en) 2020-11-12

Similar Documents

Publication Publication Date Title
CL2019003228A1 (es) Composiciones farmacéuticas de atropina.
CL2020000501A1 (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos.
CL2016000882A1 (es) Composiciones de arni contra el componente c5 del complemento y métodos para su uso (divisional de sol. n°2710-15).
AR107967A1 (es) Ácido hialurónico modificado, método para su preparación y usos del mismo
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
UY35040A (es) Pirrolopirimidinilamino-benzotiazolonas sustituidas
AR088383A1 (es) Formulaciones de etanercept estabilizadas con combinaciones de azucares y polioles
PH12017502001A1 (en) Amido-substituted cyclohexane derivatives
ECSP16084431A (es) Composiciones estables de yodo no en complejo y métodos de uso
DOP2016000042A (es) Anticuerpos contra el inhibidor del activador de plasminógeno tipo 1 (pai-1) y usos de los mismos
DOP2017000191A (es) Nuevas proteínas específicas para pioverdina y pioquelina
CR20160528A (es) Compuestos y composiciones para inducir condrogénesis
UY36460A (es) Pirazolpiridinaminas
CO2021005915A2 (es) Composiciones estables de semaglutida y usos de las mismas
AR086956A1 (es) Formulaciones liofilizadas de fgf-18
EA201590491A1 (ru) Иммуногенная композиция
BR112017024013A2 (pt) composições compreendendo células tronco mesenquimatosas e seus usos
BR112016022394A2 (pt) Composição farmaceuticamente aceitável, composição na forma de uma solução injetável farmaceuticamente aceitável, uso da composição, e, método para a preparação da composição injetável farmaceuticamente aceitável
MX2018004304A (es) DERIVADOS DE QUINOXALINA Y PIRIDOPRAZINA COMO INHIBIDORES DE PI3Kß.
UY35651A (es) Pirazolpiridinas sustituidas
MX2017011499A (es) Combinaciones de dosis fija y formulaciones que comprenden ácido 8-hidroxi-2,2,14,14 tetrametilpentadecanodioico (etc1002) y ezetimiba y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
MX2020007760A (es) Composiciones y metodos para mejorar la biodisponibilidad de 5-hidroxitriptofano.
CL2019001746A1 (es) Amidas aromáticas de ácido carboxílico
MX390384B (es) Formulaciones farmaceuticas para liberacion sostenida de ester de sebacoil dinalbufina.
EA201891848A1 (ru) Фармацевтическая композиция для применения в лечении фиброза